Search

Your search keyword '"Zimmermann, Ellen M."' showing total 391 results
Start Over Author "Zimmermann, Ellen M."
391 results on '"Zimmermann, Ellen M."'

4. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn’s Disease

Author

Al-Hawary, Mahmoud, Anupindi, Sudha, Baker, Mark E., Bruining, David, Darge, Kassa, Dillman, Jonathan, Einstein, David, Fidler, Jeff L., Fletcher, Joel G., Gee, Michael S., Grand, David, Guglielmo, Falvius, Hara, Amy K., Jaffe, Tracy A., Maglinte, Dean, Megibow, Alec, Park, Seong Ho, Platt, Joel, Podberesky, Daniel, Rimola, Jordi, Sahani, Dushyant V., Soto, Jorge, Taylor, Stuart A., Bruining, David H., Zimmermann, Ellen M., Loftus, Edward V., Jr., Sandborn, William J., Sauer, Cary G., and Strong, Scott A.

Published
2018
Full Text
View/download PDF

15. Su1020: UTILIZATION OF BIOLOGIC AGENTS AMONG HISPANIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW UPDATES

Author

Hussain, Fatima, primary, Chi, Xiaofei, additional, Gurka, Matthew, additional, Hernandez, Isabela, additional, Potlach, Tomas, additional, Setya, Aniruddh, additional, Damas, Oriana M., additional, Thompson, Lindsay A., additional, Hall, Jaclyn, additional, Abreu, Maria T., additional, Kerman, David H., additional, and Zimmermann, Ellen M., additional

Published
2022
Full Text
View/download PDF

19. Su1666: ENTEROENTERIC FISTULAE DISCOVERED ON IMAGING PREDICTS FUTURE ABDOMINAL ABSCESSES

Author

Patel, Vikas J., primary, Homsi, Maher, additional, Orriols, Nicholas, additional, Molina, Isaac L., additional, Chaudhry, Naueen A., additional, Grajo, Joseph, additional, Malkawi, Abdullah, additional, Moser, Patricia, additional, Ayoub, Fares, additional, Kaufman, Nicholas I., additional, Lambrou, Tiffany, additional, and Zimmermann, Ellen M., additional

Published
2022
Full Text
View/download PDF

28. Characteristics of Faculty at Risk of Leaving Their Medical Schools: An Analysis of the StandPoint™ Faculty Engagement Survey

Author

Zimmermann, Ellen M, Mramba, Lazarus K, Gregoire, Hamleen, Dandar, Valerie, Limacher, Marian C, and Good, Michael L

Subjects
retention, mentorship, medical school governance, Original Research, professional development
Abstract

Purpose This study seeks to identify the characteristics and attitudes of faculty in US medical colleges who are at risk of leaving their institution. Methods This research leverages data from the AAMC StandPoint Faculty Engagement Survey administered to 37,779 faculty representing 36 institutions participating during 2013–2016. Univariate and multivariable robust logistic regression models were used to assess predictors of the intent to leave based on the question: “Do you plan to leave this medical school in the next 1–2 years?”. Results Thirty percent (n=5559/18,475) of faculty responded that they were considering leaving their institution. Thirty-one percent of female faculty vs 29% of male faculty expressed an intent to leave. At-risk faculty were likely to be at junior faculty rank and at their institutions for 6–15 years vs other time periods (OR=1.16; p≤0.001). Having an administrative title (OR=0.72; p≤0.001) and receiving formal mentorship (OR=0.65; p≤0.001) were protective. Finally, faculty answering “disagree” or “strongly disagree” to any one of these StandPoint Survey questions were at > 6 fold risk of expressing an intent to leave: 1) I am satisfied with my opportunities for professional development, 2) I feel appreciated by my supervisor, 3) My day-to-day activities give me a sense of accomplishment. Conclusion Faculty expressing an intent to leave their institution have an identifiable profile. Top concerns of at-risk faculty relate to supervisory relationships and growth opportunities rather than compensation or governance. Institutional leaders should consider these factors in the development of a proactive strategy to retain talented faculty.

Published
2020

40. Characteristics of Faculty at Risk of Leaving Their Medical Schools: An Analysis of the StandPoint™ Faculty Engagement Survey

Author

Zimmermann,Ellen M., Mramba,Lazarus K., Gregoire,Hamleen, Dandar,Valerie, Limacher,Marian, Good,Michael L., Zimmermann,Ellen M., Mramba,Lazarus K., Gregoire,Hamleen, Dandar,Valerie, Limacher,Marian, and Good,Michael L.

Abstract

Ellen M Zimmermann, 1 Lazarus K Mramba, 2 Hamleen Gregoire, 3 Valerie Dandar, 4 Marian C Limacher, 5 Michael L Good 6 1Faculty Development, College of Medicine, Department of Medicine, Division of Gastroenterology, University of Florida, Gainesville, FL, USA; 2Department of Biostatistics & Data Science, University of Kansas, Kansas City, KS, USA; 3Faculty Affairs in the College of Medicine, University of Florida, Gainesville, FL, USA; 4Medical School Operations, Academic Affairs, Association of American Medical Colleges, Washington, DC, USA; 5Faculty Affairs and Professional Development, College of Medicine, Department of Medicine, Division of Cardiology, University of Florida, Gainesville, FL, USA; 6University of Utah School of Medicine, Health Sciences, University of Utah, Salt Lake City, UT, USACorrespondence: Ellen M ZimmermannUniversity of Florida, 1329 SW 16th ST, Suite 5251, Gainesville, FL 32608, USATel +1352-273-9474Email ezimmer2@ufl.eduPurpose: This study seeks to identify the characteristics and attitudes of faculty in US medical colleges who are at risk of leaving their institution.Methods: This research leverages data from the AAMC StandPoint Faculty Engagement Survey administered to 37,779 faculty representing 36 institutions participating during 2013– 2016. Univariate and multivariable robust logistic regression models were used to assess predictors of the intent to leave based on the question: “Do you plan to leave this medical school in the next 1– 2 years?”.Results: Thirty percent (n=5559/18,475) of faculty responded that they were considering leaving their institution. Thirty-one percent of female faculty vs 29% of male faculty expressed an intent to leave. At-risk faculty were likely to be at junior faculty rank and at their institutions for 6– 15 years vs other time periods (OR=1.16; p≤ 0.001). Having an administrative title (OR=0.72; p≤ 0.001) and receiving formal mentorsh

Published
2020

42. IGF-I increases IGFBP-5 and collagen [[alpha].sub.1](I) mRNAs by the MAPK pathway in rat intestinal smooth muscle cells

Author

Xin, Xiping, Hou, Yong Tai, Li, Lina, Schmiedlin-Ren, Phyllissa, Christman, Gregory M., Cheng, Hsin-Lin, Bitar, Khalil N., and Zimmermann, Ellen M.

Subjects
Insulin-like growth factor 1 -- Research, Biological sciences
Abstract

IGF-I is a potent fibrogenic growth factor that stimulates proliferation of intestinal smooth muscle cells and increases synthesis of collagen and IGF-l-binding proteins by the cells. These processes contribute to intestinal fibrosis that develops in patients with Crohn's disease and in Lewis-strain rats with experimental Crohn's disease. The aim of this study was to determine which early docking proteins are associated with IGF-I receptor signal transduction and which transduction pathway is involved in IGF-I-mediated gene regulation in intestinal smooth muscle cells. Primary cultures of smooth muscle cells isolated from the muscularis externa of the distal colon of Lewis rats were treated with IGF-I (100 ng/ml). Immunoprecipitation studies demonstrated that IGF-I stimulation resulted in tyrosine phosphorylation of IRS-1, IRS-2, and Shc. Coimmunoprecipitation demonstrated a close association between the IGF-I receptor and these three early docking proteins. Concurrent treatment with the MAPK inhibitor PD98059 (10 [micro]M) resulted in an inhibition of the IGF-I-mediated increase in IGFBP-5 and collagen [[alpha].sub.1](I) mRNAs, while concurrent treatment with the phosphatidylinositol 3-kinase (PI3-K) inhibitor wortmannin (100 nM) had no effect. In additional experiments, cells were transiently transfected with adenoviral vectors dominantly expressing inactive mutant Akt or constitutively expressing wild-type Akt. In both cases, the IGF-I-mediated increase in collagen I protein did not differ from that observed in control cultures that had been transfected with an adenoviral vector carrying the LacZ reporter gene. These results suggest that the MAPK pathway is key to IGF-I-mediated gene regulation in intestinal smooth muscle cells, whereas data do not suggest a role for the Akt-dependent pathway in our system. insulin-like growth factor I; signal transduction; Crohn's disease; inflammatory bowel disease

Published
2004

44. PLA 2 -Triggered Activation of Cyclosporine-Phospholipid Prodrug as a Drug Targeting Approach in Inflammatory Bowel Disease Therapy.

Author

Markovic, Milica, Ben-Shabat, Shimon, Nagendra Manda, Jagadeesh, Abramov-Harpaz, Karina, Regev, Clil, Miller, Yifat, Aponick, Aaron, Zimmermann, Ellen M., and Dahan, Arik

Subjects
PRODRUGS, INFLAMMATORY bowel diseases, BRUSH border membrane, TARGETED drug delivery, THERAPEUTICS, ORAL medication, GASTROINTESTINAL system
Abstract

Oral medication with activity specifically at the inflamed sites throughout the gastrointestinal tract and limited systemic exposure would be a major advance in our therapeutic approach to inflammatory bowel disease (IBD). For this purpose, we have designed a prodrug by linking active drug moiety to phospholipid (PL), the substrate of phospholipase A2 (PLA2). PLA2 expression and activity is significantly elevated in the inflamed intestinal tissues of IBD patients. Since PLA2 enzyme specifically hydrolyses the sn-2 bond within PLs, in our PL-based prodrug approach, the sn-2 positioned FA is replaced with cyclosporine, so that PLA2 may be exploited as the prodrug-activating enzyme, releasing the free drug from the PL-complex. Owing to the enzyme overexpression, this may effectively target free cyclosporine to the sites of inflammation. Four PL-cyclosporine prodrugs were synthesized, differing by their linker length between the PL and the drug moiety. To study the prodrug activation, a novel enzymatically enriched model was developed, the colonic brush border membrane vesicles (cBBMVs); in this model, tissue vesicles were produced from colitis-induced (vs. healthy) rat colons. PLA2 overexpression (3.4-fold) was demonstrated in diseased vs. healthy cBBMVs. Indeed, while healthy cBBMVs induced only marginal activation, substantial prodrug activation was evident by colitis-derived cBBMVs. Together with the PLA2 overexpression, these data validate our drug targeting strategy. In the diseased cBBMVs, quick and complete activation of the entire dose was obtained for the 12-carbon linker prodrug, while slow and marginal activation was obtained for the 6/8-carbon linkers. The potential to target the actual sites of inflammation and treat any localizations throughout the GIT, together with the extended therapeutic index, makes this orally delivered prodrug approach an exciting new therapeutic strategy for IBD treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. 812 PREOPERATIVE SARCOPENIA IS A RISK FACTOR FOR INFECTIOUS COMPLICATIONS AND PROLONGED STAY IN CROHN'S DISEASE PATIENTS UNDERGOING INTESTINAL RESECTION.

Author

Ouni, Ahmed, primary, Ayoub, Fares, additional, Jacobs, Chelsea, additional, Gesiotto, Francesca M., additional, Lopez, Anne, additional, Grajo, Joseph, additional, Kamel, Amir Y., additional, Chaudhry, Naueen A., additional, Tan, Sanda, additional, Read, Thomas, additional, and Zimmermann, Ellen M., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results